NovaBridge Biosciences (NBP) shareholders
Close on Nov 17, 2026Market cap $94.88MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Everest Medicines Limited | 42,524,716 | 16.10% | 13D (active) | Aug 5, 2025 |
| Wei Fu Joint filing with C-Bridge Capital GP, Ltd. (8.80%), C-Bridge Healthcare Fund II, L.P. (5.30%) and 1 more | 30,499,709 | 11.50% | 13D (active) amendment | Jan 29, 2026 |
| Jingwu Zhang Zang | 10,454,937 | 5.60% | 13G (passive) amendment | Dec 31, 2023 |
| T Investment Limited | 8,172,022 | 9.89% | 13D (active) | Nov 22, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NBP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hhlr Advisors, Ltd. | 5,980,568 | 2.25% | $11.66M | – | 1.40% |
| Morgan Stanley | 3,653,228 | 1.38% | $7.12M | −184,970 | 0.00% |
| AIHC Capital Management Ltd | 2,878,033 | 1.08% | $5.61M | +615,100 | 5.38% |
| Siren, L.L.C. | 2,004,739 | 0.76% | $3.91M | −995,261 | 0.08% |
| Marshall Wace, Llp | 1,231,946 | 0.46% | $2.40M | New | 0.00% |
| Candriam S.C.A. | 1,132,563 | 0.43% | $2.21M | – | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 1,000,000 | 0.38% | $1.95M | – | 0.00% |
| Two Sigma Investments, LP | 851,348 | 0.32% | $1.66M | New | 0.00% |
| Renaissance Technologies LLC | 758,226 | 0.29% | $1.48M | +485,814 | 0.00% |
| BlackRock, Inc. | 686,208 | 0.26% | $1.34M | +58,712 | 0.00% |
| Citadel Advisors LLC | 622,831 | 0.23% | $1.21M | +456,215 | 0.00% |
| E Fund Management Co., Ltd. | 589,020 | 0.22% | $1.15M | New | 0.03% |
| Exome Asset Management LLC | 576,960 | 0.22% | $1.13M | – | 0.69% |
| State Street Corp | 360,376 | 0.14% | $702.73K | −9,731 | 0.00% |
| Woodline Partners LP | 350,000 | 0.13% | $682.50K | −350,000 | 0.00% |
| Fiera Capital Corp | 315,681 | 0.12% | $615.58K | – | 0.00% |
| UBS Group AG | 301,780 | 0.11% | $588.47K | +238,239 | 0.00% |
| Barclays PLC | 279,019 | 0.11% | $544.09K | −20,280 | 0.00% |
| Taikang Asset Management (Hong Kong) Co Ltd | 170,931 | 0.06% | $333.32K | – | 0.03% |
| Goldman Sachs Group Inc | 161,321 | 0.06% | $314.58K | +48,858 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 49 | 25M | 9.3% | 13 / 13 | 11 / 11 | 5M | 4M |
| Q1 2026 | 48 | 29M | 11.0% | 9 / 14 | 15 / 18 | 3M | 7M |
| Q4 2025 | 57 | 33M | 12.5% | 21 / 16 | 12 / 5 | 9M | 5M |
| Q3 2025 | 42 | 30M | 11.2% | 21 / 10 | 6 / 11 | 21M | 1M |
| Q2 2025 | 32 | 9M | 3.5% | 10 / 5 | 8 / 7 | 1M | 1M |
| Q1 2025 | 29 | 9M | 3.4% | 5 / 5 | 5 / 3 | 1M | 4M |
| Q4 2024 | 28 | 12M | 4.5% | 7 / 3 | 6 / 7 | 4M | 7M |
| Q3 2024 | 28 | 14M | 5.3% | 4 / 5 | 6 / 13 | 0M | 1M |
| Q2 2024 | 38 | 15M | 5.7% | 3 / 4 | 19 / 4 | 4M | 1M |
| Q1 2024 | 39 | 12M | 4.6% | 6 / 11 | 9 / 11 | 2M | 3M |
| Q4 2023 | 44 | 13M | 4.8% | 11 / 11 | 14 / 13 | 2M | 4M |
| Q3 2023 | 47 | 15M | 5.7% | 12 / 9 | 14 / 12 | 2M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
17 funds held NBP in Q1 2026, 85% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NBP | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Biotechnology ETF | 591,381 | 0.22% | $1.15M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio Emerging Markets ETF | 297,847 | 0.11% | $580.80K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 68,849 | 0.03% | $126.68K | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF | 48,319 | 0.02% | $94.22K | 0.01% | Jun 30, 2026 |
| World ex U.S. Core Equity Portfolio | 26,330 | 0.01% | $42.13K | 0.00% | Jul 31, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 23,427 | 0.01% | $43.11K | 0.23% | May 31, 2026 |
| Emerging Markets Core Equity 2 Portfolio | 20,035 | 0.01% | $32.06K | 0.00% | Jul 31, 2026 |
| Emerging Markets Social Core Equity Portfolio | 15,130 | 0.01% | $24.21K | 0.00% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) China ETF | 14,210 | 0.01% | $27.71K | 0.01% | Jun 30, 2026 |
| Emerging Markets Sustainability Core 1 Portfolio | 9,306 | 0.00% | $14.89K | 0.00% | Jul 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 5,925 | 0.00% | $10.90K | 0.02% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 5,100 | 0.00% | $9.95K | 0.00% | Jun 30, 2026 |
| ProShares Ultra Nasdaq Biotechnology | 4,151 | 0.00% | $7.64K | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Srishti Gupta | Chief Executive Officer, Director | – | – | Jul 8, 2026 |
| Xi-Yong Fu | See Remarks, Director | 59,823 | 0.02% | Mar 18, 2026 |
| Charles Silberstein | Chief Financial Officer | – | – | Nov 2, 2026 |
| Phillip Andrew Dennis | Chief Medical Officer | 173,427 | 0.07% | Sep 21, 2026 |
| Sean Wuxiong Cao | Chief Bus. Development Officer | 266,467 | 0.10% | Sep 11, 2026 |
| Cong Claire Xu | EVP, Clinical Development | 304,201 | 0.11% | Sep 1, 2026 |
| Mark Arnold Hagler | Chief Commercial Officer | 230,000 | 0.09% | Jul 10, 2026 |
| Liwei Lorraine Lin | General Counsel | – | – | Jul 10, 2026 |
| Denny Hsueh Wen Chu | See Remarks | – | – | Mar 24, 2026 |
| Xiaofan Neo Zhang | Chief Investment Officer | 874,000 | 0.33% | Mar 18, 2026 |
| Ming Kyler Lei | Chief Financial Officer | – | – | Mar 18, 2026 |
| Adeline Yi Zhang | Global Controller | – | – | Mar 18, 2026 |
| Joanna Xuqiong Wu | See Remarks | 5,750 | 0.00% | Mar 18, 2026 |
| Ian Ying Woo | Director | 13,271 | 0.01% | Oct 19, 2026 |
| Martin William Dewhurst | Director | – | – | Sep 10, 2026 |
| Robert A. Lenz | Director | 17,218 | 0.01% | Aug 25, 2026 |
| Wei Fu | Director | 30,499,699 | 11.49% | Jun 30, 2026 |
| Conor Chia-hung Yang | Director | – | – | Apr 1, 2026 |
| Chun Kwok Alan Au | Director | – | – | Mar 18, 2026 |
| Xin Liu | Director | – | – | Mar 18, 2026 |
| Emmett Cunningham | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ian Ying Woo Director | Oct 15, 2026 | Option exercise | +13,271 | – | – | 13,271 |
| Phillip Andrew Dennis Chief Medical Officer | Sep 18, 2026 | Sale | −8,209 | $0.71 | $5.83K | 173,427 |
| Phillip Andrew Dennis Chief Medical Officer | Sep 17, 2026 | Option exercise | +23,695 | – | – | 181,636 |
| Sean Wuxiong Cao Chief Bus. Development Officer | Sep 9, 2026 | Sale | −107,978 | $0.74 | $79.90K | 266,467 |
| Sean Wuxiong Cao Chief Bus. Development Officer | Sep 3, 2026 | Option exercise | +235,136 | – | – | 270,209 |
| Sean Wuxiong Cao Chief Bus. Development Officer | Sep 3, 2026 | Option exercise | +104,236 | – | – | 374,445 |
| Cong Claire Xu EVP, Clinical Development | Aug 31, 2026 | Sale | −3,282 | $0.79 | $2.59K | 304,201 |
| Cong Claire Xu EVP, Clinical Development | Aug 30, 2026 | Option exercise | +9,382 | – | – | 307,483 |
| Robert A. Lenz Director | Aug 22, 2026 | Option exercise | +17,218 | – | – | 17,218 |
| Cong Claire Xu SVP, Clinical Development | Jul 6, 2026 | Sale | −4,485 | $0.89 | $3.99K | 298,101 |
| Cong Claire Xu SVP, Clinical Development | Jul 4, 2026 | Option exercise | +12,432 | – | – | 302,586 |
| Phillip Andrew Dennis Chief Medical Officer | Jun 18, 2026 | Sale | −8,494 | $0.66 | $5.61K | 157,941 |
| Phillip Andrew Dennis Chief Medical Officer | Jun 17, 2026 | Option exercise | +23,695 | – | – | 166,435 |
| Cong Claire Xu SVP, Clinical Development | Jun 1, 2026 | Sale | −3,494 | $3.94 | $13.77K | 290,154 |
| Cong Claire Xu SVP, Clinical Development | May 30, 2026 | Option exercise | +9,382 | – | – | 293,648 |
| Sean Wuxiong Cao See Remarks, Director | May 14, 2026 | Sale | −21,399 | $1.99 | $42.58K | 35,073 |
| Mark Arnold Hagler See Remarks | Apr 24, 2026 | Buy | +230,000 | $2.51 | $577.30K | 230,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NovaBridge Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,698,259 shares on Sep 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Phillip Andrew Dennis Chief Medical Officer | Sep 18, 2026 | 3,569 | $5.80K | Sep 18, 2026 | Restricted Stock Vesting |
| Sean Wuxiong Cao Officer, CHIEF BUSINESS DEVELOPMENT OFFICER | Sep 9, 2026 | 46,947 | $79.38K | Sep 9, 2026 | RESTRICTED STOCK UNITS VESTING |
| Sean Wuxiong Cao Officer, CHIEF BUSINESS DEVELOPMENT OFFICER | May 14, 2026 | 9,304 | $18.53K | May 14, 2026 | RESTRICTED SHARE UNITS VESTING |
| Phillip Andrew Dennis Chief Medical Officer | Mar 18, 2026 | 3,638 | $10.15K | Mar 18, 2026 | Restricted Stock units Vesting |
| Skelton Joseph W. Officer, FORMER CFO | Jan 2, 2026 | 120,000 | $519.60K | Jan 2, 2026 | STOCK OPTION EXERCISE AND SALE PURSUANT TO 10B51 PLAN |
| Phillip Andrew Dennis CHIEF MEDICAL OFFICER | Dec 18, 2025 | 3,431 | $14.50K | Dec 18, 2025 | Restricted Stock Units Vesting |
| Kannan Raj Officer, CEO | Jul 26, 2024 | 50,000 | $69.50K | Jul 26, 2024 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Kannan Raj Officer, CEO | Jul 17, 2024 | 300,000 | $489.00K | Jul 17, 2024 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Feng Gigi Qi Officer, CHIEF COMMUNICATIONS OFFICER | Mar 15, 2024 | 150 | $270 | Mar 15, 2024 | ACQUIRED STOCK UNDER THE COMPANY SHARE INCENTIVE PLAN |
| Tang Weimin Officer, CHIEF BUSINESS OFFICER | Feb 8, 2024 | 20,000 | $40.00K | Feb 8, 2024 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Zhu Andrew Officer, PRESIDENT AND ACTING CEO | Jan 5, 2024 | 30,000 | $63.60K | Jan 5, 2024 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Li Richard Cheng Officer, CHIEF LEGAL OFFICER | Dec 29, 2023 | 85,700 | $156.83K | Dec 29, 2023 | ACQUIRED STOCK NDER COMPANY SHARE INCENTIVE PLAN |
| Feng Gigi Qi Officer, CHIEF COMMUNICATION OFFICER | Dec 26, 2023 | 20,000 | $31.00K | Dec 26, 2023 | ACQUIRED STOCK NDER COMPANY SHARE INCENTIVE PLAN |
| Li Richard Cheng Officer, CHIEF LEGAL OFFICER | Nov 16, 2023 | 85,700 | $147.40K | Nov 16, 2023 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Everest Medicines Ltd 10% Stockholder | Oct 10, 2023 | 6,078,555 | $4.47M | Oct 24, 2023 | Private placement |
See a number that looks wrong?